Edward Carr
Known title: CHIEF ACCOUNTING OFFICERCIK: 0001273351
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Transaction History
| DNTH | ▲ Buy | Option Exercise | 20,000 | $358K | 9/17/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 7,928 | $796K | 9/17/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 6,771 | $686K | 9/17/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 3,501 | $358K | 9/17/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 1,100 | $114K | 9/17/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 700 | $73K | 9/17/2026 | View on chart |
| DNTH | ▲ Buy | Option Exercise | 10,000 | $218K | 3/12/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 15,852 | $1.3M | 3/12/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 200 | $17K | 3/12/2026 | View on chart |
| DNTH | ▲ Buy | Option Exercise | 16,182 | $289K | 3/12/2026 | View on chart |
| DNTH | ▲ Buy | Option Exercise | 17,500 | $386K | 3/12/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 3,865 | $319K | 3/12/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 300 | $26K | 3/12/2026 | View on chart |
| DNTH | ▼ Sell | Open Market | 23,465 | $1.9M | 3/12/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 29,122 | $31K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants
Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants. Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.